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Abstract 
An overview is given of the primary basis for the scientific inference that 
somidobove sustained release injection is safe for multiparous dairy cows. 
The process of analysis and interpretation of the voluminous data collected 
from a target animal safety study which started with 28 cows and lasted two 
lactations is described. This was a repeated measures study with most of 
60 variables being measured or summarized every 28 days resulting in 
approximately 1500 measurements per cow. The statistical analysis was 
designed to screen the variables for biological change caused by treatment 
and consisted of a univariate analysis of variance for repeated measures 
data both wi thin a lactation and across two lactations. Graphs of least 
squares means with error bounds and p-value plots of ANOVA p-values helped 
communicate statistical findings. A cross disciplinary approach inter-
preted analyses and arrived at inferences. 
Key Words: repeated measures, p-value plots 
I. INTRODUCTION 
Obtaining Food and Drug Administration approval to sell a nevi product to 
U. S. dairymen to increase efficiency of milk production requires, inter 
alia, that its use be shown to be safe to dairy co,,'s. A key element in the 
process of demonstrating safety of an animal drug is a safety study in the 
species for which the product is intended to be used. Target animal safety 
studies (TASS) are usually designed such that three groups of animals 
treated with the drug at IX, 3X, and 5X the intended use level are compared 
to an untreated control group. The intent is to determine whether the 
efficacious, recommended use level OX) causes adverse effects. The 5X 
level should identify variables of greatest sensitivity to toxicologic 
impact and allow an estimate of the magnitude of the toxicity. The 3X 
level improves the chances of achieving both objectives. 
II. MATERIAL AND METHODS 
In order to provide an in-depth safety profile for somidobove, a form of 
bovine somatotropin produced by recombinant DNA technology, a TASS was 
conducted with the product on 28 multiparous dairy cattle under simulated 
field use conditions during two consecutive lactations. Individual animal 
(quantitative) response observations were determined for 60 variables 
(Table 1) at frequencies that varied from twice daily (yield milk) to once 
every three months (milk phosphorus concentration). These attributes 
together with the biologists' preference for univariate tests at each 
sampling in time, over multivariate t)~e analyses, made summarization 
and analysis a challenge. 




The 28 animals were distributed across treatment classes as follows: 




















Dropouts from multilactation dairy trials are unavoidable; this complicated 
analysis. 
To focus attention on variables affected by treatment, to avoid missing 
potential problems, and yet to keep analysis understandable, we utilized 
the two types of analyses -- wi thin lactation and lactations combined --
described below. 
Within Lactations 
Somidobove was injected subcutaneously every 28 days for 10 consecutive 
treatments; 36 variables were measured in blood samples collected every 28 
days. For a large majority of the variables, summarization of the data by 
28-day period means allowed treatment effects within a single lactation to 
be evaluated. 
To identify variables most sensitive to somidobove over time within each 
lactation, the following statistical screen devised in consultation ,,"ith 
the FDA Center for Veterinary Medicine personnel was implemented. Forty 
variables either observed every 28 days, or summarized on a 28-day basis, 
were analyzed by the following model: 
lactation 1 lactation 2 
Source df df 
Treatment 3 3 
Cows (treatment) 24 19 
Period 9 9 
Treatment x period 27 27 
Error 205 163 
This analysis was appropriately modified for variables observed every three 
months within each lactation. 
Furthermore, treatment x period effect was partitioned into three component 
effects: 
• control vs 960 mg x period 
• control vs 2880 mg x period 
• control vs 4800 mg x period 
In this model, period was a repeated measures effect and treatment x period 
effect reflected changes that occur in treatment effects over time during 
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the lactation. Concatenation of period mean values over two lactations 
onto one graph provided an effective way to visually demonstrate the 
exquisite sensitivity of this screen (Figure 1). 
Lactations Combined 
To satisfy the second objective of determining long-term administration 
(two lactation) effects, all observations for a variable during each 
lactation were averaged into a single value. Lactation summary values were 
the observations employed in this statistical analysis to estimate response 
to treatments. 
Treatments were assigned 
the experimental unit. 
analysis was: 
to animals only once, making the individual animal 













Lactation was a repeated measures effect in the statistical model The 
treatment x lactation interaction effect reflected changes that may occur 
in treatment effect from the first to the second lactation. Cows (treat-
ment) was the error term for testing treatment effects and contrasts in 
this model. 
In this TASS sixty quanti tati ve variables (Table 1) required analysis. 
Fisher (1937) discussed analysis of variance CANOVA) in the context of one 
or perhaps only a few variables. Consequently, to avoid being misled by 
random chance variation, a global view of the study was needed. To do 
this, a p-value plot of all variables collected, a technique exemplified by 
Schweder and Spj otvoll (1982), was used. Theory says that in a p-value 
plot of ANOVA p-values all points corresponding to true null hypotheses 
should approximate a straight line, while those representing false null 
hypotheses should deviate from the line. The line can, therefore, be used 
to estimate the number of true null hypotheses. Two biologically similar 
measures like MeR and MCV are statistically independent enough in realiza~ 
tion, i.e. measurement error, for the approach to be practical in a multi-
variable TASS. This approach was applied separately first to test treat-
ment x lactation (Figure 5), and also to all three contrasts of primary 
interest (control vs 960 mg group, control vs 2880 mg group, and control vs 
4800 mg group). 
III. RESULTS A1~ DISCUSSION 
Within Lactations 
A variable adversely affected by somidobove over time would exhibit a 
profile not parallel to that of the control. A sensitive indicator of this 
non-parallelism (i.e. variables that increase as well as those that 




decrease compared to control) was provided by the treatment contrast by 
period interaction. A significant contrast x period interaction selected 
variables in need of biological evaluation; if significance occurred for 
any variable for any of these interactions for either first or second 
lactation, then graphs of treatment x period least squares means ± standard 
error for the affected variable were made to assist in a biological evalu-
ation of the finding. An example analysis of variance with treatment 
contrast by period interactions highlighted is in Table 2. A summary of 
contrast p-values is shown in Table 3; graphs for a selected few variables 
appear in Figures 1 - 4. 
Making a complete graphic necessitated 'pretreatment' or covariate least 
squares mean values be plotted as period/month 0 (beginning of lactation 1) 
and 15 (beginning of lactation 2). These means ± standard errors were 
obtained by reapplying a similar analysis to a dataset restricted to 
consist of observations obtained at these times. 
Statistical science is a powerful aid to inference not a panacea. The 
error terms used in the above statistical screen are auto-correlated ones, 
known to be too small, and thus prone to give false signals that something 
other than random variability has influenced the result. They have 205 and 
163 degrees of freedom in lactation 1 and 2, respectively, and are compiled 
from repeated measures over time from the same individual; "statistically" 
independen t they may be, "biologically" independent they are not. Green-
house and Geisser (1959) suggested making the test with degrees of freedom 
divided by the number of periods less one to reduce spurious significance. 
Conversely, Huynh and Feldt (1970) showed these tests were valid F-statis-
tics (with a df multiplier (£) equal to one) if, and only if, all possible 
time differences x.-x. (i~j) are equally variable. Homeostatic TASS 
variables over timel appear to be a tailor-made example requiring no £ 
correction to be made. 
A 'significant' (p<. 002) control vs 2880 mg x period value for aspartate 
transaminase (AST) , in lactation 1 (Tables 2 and 3, Figure 1) draws atten-
tion to the different amount of white space between the two relevant bounds 
over periods. In particular, none prior to period 4, a noticeable amount 
for one period, and then a small amount for the remainder of lactation 1. 
Failure of the finding to repeat in lactation two or for the 4800 mg 
contrast to reinforce the finding make it less than compelling. 
Borderline significance occurred on two occasions for Albumin/Globulin 
(A/G) ratio for control vs 2880 mg x period (Table 3, Figure 2). Evi-
dently, the test was highly sensitive to idiosyncrasy in the crossing-
over patterns of the two bounds. The finding was not repeated for 4800 mg 
despite an equally disparate set of bounds; and the more reason why border-
line significance (p~.05) on a single occasion is shaky statistical grounds 
for a claim that something other than random variability has influenced the 
result. 
Systematic scrutiny of the plots of the 19 variables that had at least one 
significant contrast interaction listed in Table 3 identify only somidobove 
level in the blood CBST) and the erythrocytic variables to be showing more 
than random variation during somidobove treatment. Somidobove level in 
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blood tended to increase with time during the first lactation but not 
during the second lactation. 
Erythrocytic Variables: Contrasts of control vs. 2880 X period and control 
vs. 4800 X period were consistently at or below a probability of 0.01 for 
mean corpuscular volume (MCV) and mean corpuscular hemoglobin (riCR) in both 
Lactations 1 and 2 (Table 1). In addition, contrasts of control vs 4800 X 
period for erythrocyte count were significant (P=.05) in Lactation 2 only 
(Table 3). None of the six contrasts is significant for either packed cell 
volume (PCV) or hemoglobin concentration (HGB). 
Changes in erythrocytic variables are generally interrelated. Therefore, 
any changes in erythrocyte count, hemoglobin concentration and PCV should 
affect the MCV and MCR values as well. But in this interaction screen 
confidence bounds for MeV (Figure 3) and MCH (Figure 4) were less parallel 
over the lactation than the corresponding ones for pev and RGB. 
The slight changes in MeV and MeR in the absences of corresponding changes 
in other erythrocytic variables may be explained by the fact that long-term 
intramuscular or subcutaneous administration of a compound often causes 
minor inflammatory reactions at the injection sites. Observation of 
dose-related minor irritation at the injection sites in this study was the 
case. It is known that any inflammatory reaction will perturb erythro-
poiesis resulting in production of red cells with reduced MeV and MeR 
(Jain, 1968). Fluctuation in erythrocytic variables is reported to be 
common in bovine species during the first few years of life before becoming 
stabilized (Jain, 1986). High producing cows often have lower hemoglobin 
concentration than low producing cows (Whitlock et a1., 1974). 
While erythrocyte count, 
figures for MeV and MeR, 
cantly, in a dose related 
are well within the normal 
Lactations Combined 
hemoglobin concentration and PCV, like in the 
tend to be reduced slightly, sometimes signifi-
fashion with somidobove dosage, all mean values 
ranges for these variables. 
A sample of analysis of variance for data ""ith lactations combined is in 
Table 4. The variable is calving interval and p-values for treatment x 
lactation, control vs 4800 mg, and control vs 960 mg appear in Figures 5, 6, 
and 7, respectively. 
Lactation x Somidobove Level: Figure 5 shows a p-value plot of all tests 
of Treatment x Lactation effect for multiparous cows. The plot shows 
excellent conformity with a "45 0 line plot". Such agreement indicated the 
experiment viewed as a whole provides no evidence that treatment effects 
for cows are different in the two lactations tested. 
The p-value plot technique isolated easily the following situation which 
has a ready explanation for why it is "unusual". Mean birth weights in 
lbs of calvings by lactation and multiplicity were: 




Lactation Control 960 mg 2880 mg Li S80 mg 
Single Birth Calvings 
1 106.7 97.6 103.3 92.0 
(6) (5 ) (3) (6) 
2 105.4 109.8 108.0 60.0 
(5 ) (4) (1) (1) 





Numbers in parentheses indicate numbers of births. 
Somidobove at 960 mg appears to have no detrimental effect on calf weight. 
It may appear prudent to draw the inference from this table that the 4800 
mg level begins to impact calf weight in the second lactation. An alterna-
tive simple explanation is by chance more twins Ylere in the 4800 mg group; 
all that is being detected is that twins are smaller and weigh less than 
calves of single births. 
Control vs 4800 mg somidobove: Figure 6 shows the classic "two intersect-
ing lines" pattern; the intersection point provides a good cut-point or 
signal of variables affected by the 4800 mg somidobove level. Indeed 
scientific evaluation needs to focus only on variables listed above where 
two lines intersect (albumin globulin ratio, AG_RA); only they exhibit 
contrast probabilities that are beyond chance expectation under the null 
hypothesis. 
Control vs 960 mg somidobove: The two-lactation average milk production 
increase estimate due to 960 mg is a respectable 2.43 kg/day (P level = 
.22); small sample size and an imbalanced sample have likely contributed to 
the non-significance of this result. Figure 7 shows the p-value plot for 
control vs ':;lOU mg som~aoDove. This plot shows 960 mg somidobove to be 
without effect on the 60 variables tested. 
IV. CONCLUSIONS 
The auto-correlated error used to signal treatment effects over time in the 
within-lactation analyses gave many false positive signals; the plots of 
means over time ± standard error bounds, p~value magnitude and biological 
knowledge easily screened out such 'spurious' significances. 
This small two lactation study confirms that somidobove increases fat 
corrected milk and milk yield. In cows, the 4800 mg level produces yield 
effects in the 4-5 kg/day range; the quality of milk was unaffected. 
Increased milk production evidently stimulates a corresponding small 
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increase in dry matter intake. When this is not sufficient to sustain all 
the increased production, body- fat stores are utilized. Rate of weight 
gain and average body weight all reflect this self-limiting process; cows 
on 960 - 4800 mg somidobove weighed about 25 kg less at the end of their 
lactations than did comparable controls. 
At the highest level of somidobove (4800 mg) clinical chemistry and hema-
tology variables affected were blood urea nitrogen, total protein, globu-
lin, albumin globulin ratio, mean corpuscular volume, thrombocytes, mean 
corpuscular hemoglobin, packed cell volume, hemoglobin and eosinophils. 
The low level (960 mg) showed no effect on these variables. 
A review of all the variables 'V"hich were tested in this study did not 
reveal any biologically significant changes that would preclude the safe 
use of somidobove in multiparous dairy cows. 
V. ACKNOWLEDGEMENT 
Consultation and advise of Robert J. Condon, Ph.D.; Margaret T. Roper, MS; 
and Richard P. Lehmann, Ph. D. of the Center for Veterinary Medicine, U. S. 
Food and Drug Administration is acknowledged. 
REFERENCES 
Fisher, R. A. (1937). "The Design of Experiments", 2nd Edition, Pg. 57. 
Oliver and Boyd, London. 
Greenhous e, S. W. and Geisser S. (1959). On Methods in the Analysis of 
Profile Data. Psvchometrika 24:95-112. 
" 
Huynh, H. and Feldt, L. S. (1970). Conditions Under w,.'lich Mean Square 
Ratios in Repeated Measurements Designs have Exact F Distributions. 
Journal of the American Statistical Association 65:1582-1589. 
Jain, N. 
179. 
C. 1986. Schalm's Veterinary Hematology, 
Lea and Febiger, Philadelphia. 
Jain NC, Editor, Pg. 
Schweder, T. and Spjotvoll, E. (1982). Plots of p-values to evaluate many 
tests simultaneously. Biometrika 69:493-502. 
wnitlock, R~ H .. , W .. Little, and G. J. ROvllands (1974). The incidence of 
anemia in aa~ry cows in relation to season, milk yield and age. 
Research in Veterinary Science 16:122. 




TABLE 1. SOMIDOBOVE TARGET ANIMAL SAFETY STUDY T4UVX8516 
Variables Analyzed 
AG_RA Albumin globulin ratio NEUT Neutrophil 
ALB Albumin PCV Packed cell volume 
ALP Alkaline phosphatase TIIRMB Thrombocytes 
AST Aspartate transaminase BST Bovine somatotropin 
BND Bands INSUL Insul in 
BUN Blood urea nitrogen T4 Th yroxin e 
CA Calcium B_WT Body weight 
CIIOL Cholesterol BREI Breeding interval (days 
Q, Chloride to first breeding) 
CREAT Creatinine CALFII Calf height 
GLOB Globulin CALFL Calf length 
GLU Glucose CALFW Calf weight 
U)IlO Inorganic phosphorus CALVI Calving interval 
K Potassium DAYSM Days milked 
NA Sodium DAYSO Days open 
SDII Sorbitol dehydrogenase DMI Dry matter intake 
SZINC Serum zinc F_EST First estrus 
T_BlL Total bi Hru bin GE..'U Gestation interval 
T_Pro Total protein MCALC Milk calcium 
TRIGL Triglycerides MFAT Milk fat 
BASO Basophils MLACT Milk lactose 
EOS Eosinophils MPHOS Milk phosphorus 
ERYS Erythrocytes MPROT Milk protein 
IH3 Hemoglobin I'vITSOL Milk total solids 
LEUK Leukocytes MllNC Milk zinc 
LYMPH Lymphocytes NEI Net energy intake 
lVRJI Mean corpuscular hemoglobin NSERV Number of services 
MellC Mean corpuscular hemoglobin S_CR Somatic cells 
concentration WT_GA Weight gain 
fIlL" Mean corpuscular volume YFCM Yield 3.5% fat 
MONO Monocytes corrected mi lk 
YMILK Yield milk 
TABLE 2. ANALYSIS OF VARIANCE OF ASPARTATE 
TRANSAMINASE (AST) DATA FROM THE FIRST 
LACTATION 
Type III 
Source .J2.F. SUlD of Squares F ~ 
Treatment 3 2362.57 9.85 0.0001 
Cow(Treatmen t) 24 14157.57 7.38 0.0001 
Period 9 2708.05 3.76 0.0002 
Trea txPerioJ 27 3673.95 1.70 0.02 J 1 
Error 205 16388.35 
COlltrast D.F. 5S F P 
Control vs 960 mg by Period 9 235.49 0.33 0.9653 
Control vs 2660 mg by Period 9 2239.49 3.11 0.0016 







































TABLE 3. SUMMARY OF SELECTED P-VAWES FOR CONTRAST X PERIOD INlERAcnON FOR TIlE TEN TREATMENT PERIODS DUlUNG EACH LACTATION 
Lflctalion 
Variable 2 Variable 
C201l11t CsmLrilL CsmLraSL 
CVlL CVIM C VI H C V5 L C V5 M C v511 C.o L Cvo M 
·AfB RATIO .95 .07 .25 .12 .05 .33 ·MCV .74 .0001 
ALB .99 .23 .35 .07 .12 .95 "M<N) .06 .53 
·ALP .01 .83 .34 .15 .68 .05 ·NA .59 .06 
·AST .97 .002 .74 .99 .98 .95 NEUf .69 .38 
BASO .62 .51 .85 .29 .52 .72 PCV .30 .21 
·BUN .47 .01 .83 .65 .22 .11 SOH .71 .35 
CA .99 .18 .51 .89 .65 .76 TBILI .99 .97 
OKll. .21 .23 .21 .20 .87 .16 +'J'PROT .95 .71 
+cL .42 .61 .02 .45 .36 .25 1lIRMB .59 .71 
CRF.AT .14 .44 .07 .22 .26 .62 TRIGL .85 .25 
"F.al .67 .76 .99 .27 .47 .05 T4 .72 .55 
·FRYS .48 .97 .80 .19 .04 .05 ·SST .96 .01 
'GUll .98 .0009 .26 .26 .17 .07 INSULIN .37 .09 
'G1lJ .10 .06 .42 .27 .60 .56 SZINC .72 .68 
1IG11 .49 .31 .91 .36 .26 .64 ·MCAL .39 .63 
·11'1I0S .54 .05 .31 .36 .92 .78 MPIIOS .61 .07 
K .89 .66 .56 .32 .94 .35 ·M71NC .09 .01 
LEUK .55 .27 .19 .23 .35 .42 ·BOOYWf_ 
LYMPH .50 .32 .44 .67 .82 .94 AVE .17 .04 
·MOI .96 .0001 .07 .08 .004 .0002 SOMATIC 
MOIC .92 .38 .58 .38 .77 .63 CEIl.SW .20 .77 
·Graphs over two lactations were made for these variables 
TABLE 4. ANALYSIS OF VARIANCE OF CALVING INTERVAL DATA FOR COWS CALVING OVER BOTJI LACTA'nONS 
Type III 












Control vs 960 mg 
Control vs 2660 mg 
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Somldobove Two Lactation Target Animal Safety Study 
Aspartate Transaminase (AST) 
= Contrnl 
= 960 mg 
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
Period/Month. 
= Control 
= 2880 mg 














= 4800 mg 
O~~I~r_~_r_.--r_~_r_.--r_~_r_,--r_-r_+-,--r__r_r--r_~_r_.--r-4__J 
o 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
I'erlod/Monlh. 
Ilounds for the treatments ore ledst squares means + or - SID Error. 
Figure 2 Somldobove Two Lactation Target Animal Safety study 
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Somldobove Two Lactation TClr!jol Animal Safety Study 
Moan Corpuscular Volume (MeV) 
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Somldobove Two Lactation Target Animal SClfoly study 
Moan Corpuscular Hemoglobin (MCH) 
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Figure 5 Distribution of Probabilities - Lactation X Somidobove Level 
Rank Variable 60 • CALFL 59 • CALFW 58 
CALFH 57 
GE~ 56 IAPHOS 55 # UST 54- # -INSUL 53 • IAZINC 52 • ~CEL 51 ~ -SOH 50 
F --.EST 4-9 • f-IATSDL 4-8 X f-IACV 4-7 . BRLJ 4-6 ~ ALB 4-5 X ·IACH 
4-4 Variable Class • f-WLGA 4-3 
f-NSERV 4-2 ~~<t Clinical chemistry IAFAT 4-1 X f-THRIAB 40 XXX Hematology <> f-TRIGL 39 X f-LYMPH 38- . . . Production • LWT 37 <> f-BNO 36 ### Hormone X f-EOS 35 ~ TYRO 34- # T4 33 
IACALC 32 • DAYSO 31 
CALVI 30 X -LEUK 29 <> f-CA 28 ~ CL 27 X BASO 26 X NEUT 25 ~ NA 
24- <> AGJA 23 X ERYS 22 <> GLU 21 <> CHOL 20 <> T.....BIL 19 X PCV 18 
YMILK 17 <> f-SZlNC 16 • IALACT 15 <> BUN 14 X IACHC 13 
DAYSIA 12 X HGB 11 <> GLOB 10 • NET 9 • DMI 8 X lAO NO 7 <> K 6 YFCM 5 <> CREAT 4 <> AST 3 lAP ROT 2 <> ALP 1 ~- LPHO 
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Figure [, Distribution of Probohilities - Control vs Sornidobove 4800 rng/28days 
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Figure 7 Distribution of Probabiliiies- Control vs Sornidobove 960 rng/;;Sdays 
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